Abstract 1441P
Background
The MORPHEUS platform was designed to accelerate development of novel cancer immunotherapy combinations across tumour types. The adaptive design of these global, open-label, randomised, phase Ib/II studies allows a single control arm to be compared with multiple experimental arms and provides the flexibility to open new arms or close existing arms. We report interim analysis results from the MORPHEUS-Lung study in CPI-experienced patients (pts) with mNSCLC.
Methods
Cohort 2 (C2) of MORPHEUS-Lung is enrolling pts with EGFR/ALK WT mNSCLC that has progressed on prior platinum and a CPI (anti–PD-L1/PD-1) given concurrently or sequentially. The primary endpoints are investigator-assessed ORR (RECIST v1.1) and safety. Secondary endpoints include PFS and OS. Biomarkers are also being explored. C2 pts with non-squamous mNSCLC randomised to the atezo + bev, atezo + bev + RT or doc (control) arms were included in the analysis. Data from the atezo + bev + RT arm will be presented at the meeting along with updated data for the atezo + bev and doc arms.
Results
At data cutoff (24 Aug 2022), the efficacy and safety populations included 72 pts (atezo + bev, n=40; doc, n=32). The median age was 63 y, 72% of pts (n=52) were male and 81% (n=58) had PD-L1+ NSCLC per local testing. Confirmed ORR was 18% (n=7) and 16% (n=5) in the atezo + bev and doc arms, respectively (Table); 1 pt (3%) had a complete response (atezo + bev). Gr 3-5 AEs occurred in 40% (n=16) and 59% (n=19) of pts in the respective arms (Table). Tx-related Gr 4/5 AEs only occurred in the doc arm.
Conclusions
MORPHEUS-Lung interim analysis results suggest that atezo + bev is a potential tx option for CPI-experienced pts with mNSCLC. No new safety signals were identified, and AEs were consistent with the known safety profiles of the individual agents. Atezo + bev was tolerable, with fewer Gr 3-5 AEs and tx withdrawals than with doc. Table: 1441P
Atezo + bev n=40 | Doc (control) n=32 | |
Response, n (%) | ||
Confirmed ORR | 7 (18) | 5 (16) |
DCR | 26 (65) | 18 (56) |
Median survival (95% CI), mo a, b | ||
PFS | 6.9 (4.3, 8.3) | 4.5 (3.4, 5.9) |
HR 0.77 (95% CI: 0.44, 1.34) | ||
OS | 13.7 (8.5, NE) | 18.6 (7.0, 21.0) |
HR 0.99 (95% CI: 0.50, 1.94) | ||
Pts with ≥1 AE, n (%) | ||
Grade 3-5 | 16 (40) | 19 (59) |
Worst Grade: 4 | 0 | 4 (13) |
Worst Grade: 5 | 0 | 1 (3)c |
Tx related | 31 (78) | 31 (97) |
Serious | 12 (30) | 8 (25) |
Leading to withdrawal from any treatment | 2 (5) | 5 (16) |
NE, not estimable. aPer RECIST 1.1. bMedian survival follow-up: atezo + bev, 8.5 mo; doc, 7.2 mo. cGrade 5 pneumonia considered by the investigator to be tx related.
Clinical trial identification
NCT03337698.
Editorial acknowledgement
Medical writing support for this abstract, furnished by Kia C. E. Walcott, PhD, of Health Interactions, Inc., was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Legal entity responsible for the study
F. Hoffmann-La Roche, Ltd.
Funding
F. Hoffmann-La Roche, Ltd.
Disclosure
F. Ghiringhelli: Financial Interests, Personal, Other, Honoraria: Roche, MSD, Serono; Financial Interests, Institutional, Research Funding: AstraZeneca, MedImmune , Roche; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Amgen, Roche, Genentech. E. Felip: Financial Interests, Personal, Advisory Board: AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Gilead, GSK, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Peptomyc, Regeneron, Sanofi, Takeda, Turning Point, Pfizer; Financial Interests, Personal, Invited Speaker: Amgen, Daiichi Sankyo, Genentech, Janssen, Medical Trends, Medscape, Merck Serono, PeerVoice, Pfizer, Sanofi, Takeda, Touch Oncology, AstraZeneca, Bristol Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Merck Sharp & Dohme; Financial Interests, Personal, Member of Board of Directors, Independent member: Grifols; Financial Interests, Institutional, Local PI, Clinical Trial: AstraZeneca AB, AbbVie, Amgen, Bayer Consumer Care AG, BeiGene, Boehringer Ingelheim GmbH, Bristol Myers Squibb International Corporation, Daiichi Sankyo Inc., Exelixis Inc., F. Hoffmann-La Roche Ltd., Genentech Inc., GSK Research and Development Limited, Janssen Cilag International NV, Merck Sharp & Dohme Corp, Merck KGAA, Mirati Therapeutics Inc, Novartis Pharmaceutica SA, Pfizer, Takeda Pharmaceuticals International; Non-Financial Interests, Leadership Role, President (2021-2023): SEOM (Sociedad Espanola de Oncologia Medica); Non-Financial Interests, Member, Member of Scientific Committee: ETOP (European Thoracic Oncology Platform); Non-Financial Interests, Member, Member of the Scientific Advisory Committee: CAC Hospital Universitari Parc Taulí. A. Zer: Financial Interests, Personal, Invited Speaker: Roche, BMS, MSD, Takeda, Pfizer, Novartis; Financial Interests, Personal, Advisory Board: AstraZeneca, Steba, Oncohost; Financial Interests, Personal, Stocks/Shares: Nixio; Financial Interests, Institutional, Research Grant: BMS. L. Greillier: Financial Interests, Personal, Advisory Board: AbbVie, AstraZeneca, BMS, MSD, Novartis, Sanofi, Takeda, Roche; Financial Interests, Personal, Invited Speaker: Lilly, Pfizer; Financial Interests, Institutional, Local PI: AstraZeneca, AbbVie, BMS, MSD, Novartis, Takeda, Pfizer, PharmaMar; Financial Interests, Institutional, Coordinating PI: Sanofi; Financial Interests, Personal, Local PI: Roche. A. Greystoke: Financial Interests, Personal, Advisory Board: BMS, AstraZeneca, Boehringer Ingelheim, Takeda, Roche, Novartis; Financial Interests, Personal, Invited Speaker: Merck, MSD, Pfizer, Janssen; Financial Interests, Institutional, Local PI: MSD; Financial Interests, Institutional, Coordinating PI: Pfizer, AstraZeneca, Novartis, Achilles; Non-Financial Interests, Advisory Role: National Institue for Health and Clinical Excellence; Other, Clinical Lead for Cancer (paid position): North East England and Yorkshire Genomic Laboratory Hub. N. Al-Sakaff: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche Ltd. H. Helms: Financial Interests, Personal, Full or part-time Employment: Roche; Financial Interests, Personal, Stocks/Shares: Roche. J.P. Pintoffl: Financial Interests, Personal, Full or part-time Employment: Roche; Financial Interests, Personal, Stocks/Shares: Roche. S. Rahalkar: Financial Interests, Personal, Full or part-time Employment: Roche; Financial Interests, Personal, Stocks/Shares: Roche. B.C. Cho: Financial Interests, Personal, Other, Consulting role: Abion, BeiGene, Novartis, AstraZeneca, Boehringer Ingelheim, Roche, BMS, CJ, CureLogen, Cyrus Therapeutics, Ono, Onegene Biotechnology, Yuhan, Pfizer, Eli Lilly, GI-Cell, Guardant, HK Inno-N, Imnewrun Biosciences Inc., Janssen, Takeda, MSD, Janssen; Financial Interests, Personal, Advisory Board: Kanaph Therapeutic Inc, BridgeBio Therapeutics, Cyrus Therapeutics, Guardant Health, Oscotec Inc; Financial Interests, Personal, Other, Advisory role: Medpacto, Blueprint Medicines, RandBio, Hanmi; Financial Interests, Personal, Member of Board of Directors: Interpark Bio Convergence Corp., J Ints Bio; Financial Interests, Personal, Stocks/Shares: TheraCanVac Inc, Gencurix Inc, BridgeBio Therapeutics, Kanaph Therapeutic Inc, Cyrus Therapeutics, Interpark Bio Convergence Corp., J Ints Bio; Financial Interests, Personal, Royalties: Champions Oncology, Crown Bioscience, Imagen; Financial Interests, Institutional, Research Grant: MOGAM Institute, LG Chem, Oscotec, Interpark Bio Convergence Corp, GIInnovation, GI-Cell, Abion, AbbVie, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Champions Oncology, CJ Bioscience, CJ Blossom Park, Cyrus, Dizal Pharma, Genexine., Janssen, Lilly, MSD, Novartis, Nuvalent, Oncternal, Ono, Regeneron, Dong-A ST, BridgeBio Therapeutics, Yuhan, ImmuneOncia, Illumina, Kanaph Therapeutics, Therapex, JINTSbio, Hanmi, CHA Bundang Medical Center; Other, Founder: Daan BioTherapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
1411P - Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04)
Presenter: Grace Dy
Session: Poster session 20
1412P - SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors
Presenter: Alessandra Curioni-Fontecedro
Session: Poster session 20
1414P - Impact of co-mutations on the prognosis of targeted therapy in EGFR-mutant advanced NSCLC: A result of real-world study
Presenter: Sisi Pan
Session: Poster session 20
1416P - Recurrence of infusion-related reaction (IRRs) associated to avimantamab
Presenter: Maria Virginia Sanchez Becerra
Session: Poster session 20
1417P - Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2019: An observational study from the French national claims database
Presenter: Christos Chouaid
Session: Poster session 20
1418P - Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study
Presenter: Rupesh Kotecha
Session: Poster session 20
1419P - TACSTD2 (Trop-2) constitutes a promising antibody-drug conjugate target for patients with non-small cell lung cancer brain metastases
Presenter: Sara Hijazo-Pechero
Session: Poster session 20
1420P - Real-life management of octogenarians with NSCLC in a French nationwide cohort
Presenter: Romain Corre
Session: Poster session 20
1421P - AI-powered intracranial tumor response predicts systemic progression with high concordance in endpoint evaluation in the phase III CROWN study
Presenter: Shao-Lun Lu
Session: Poster session 20